No Data
No Data
Express News | Avidity Biosciences Inc : Leerink Partners Cuts Target Price to $60 From $64
Avidity Biosciences, Inc. (RNA): The Biotech Stock With Biggest Upside Potential
BofA Securities Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $51
Bank of America Securities Remains a Buy on Avidity Biosciences (RNA)
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $63
Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA), Celldex (CLDX) and Centessa Pharmaceuticals (CNTA)